comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 09:26:16 - browse：2

Robert F. Kennedy Jr. arrives in the lobby of Trump Tower in New York for a meeting with President-elect Donald Trump. Evan Vucci/AP

WASHINGTON — Outspoken vaccine critic Robert Kennedy Jr. said Tuesday that he had accepted a position in Donald Trump’s administration as chair of a panel on vaccine safety and scientific integrity, in what would be the clearest sign yet of the president-elect’s suspicions about vaccines.

Kennedy’s remarks followed his meeting with the president-elect at Trump Tower and immediately sparked outrage from scientists, pediatricians, and public health experts, who fear the incoming administration could give legitimacy to skeptics of childhood immunizations despite a huge body of scientific research demonstrating that vaccines are safe. Many of those skeptics believe vaccines are a cause of autism.

Hours later, Trump spokeswoman Hope Hicks said in a statement that the president-elect was “exploring the possibility of forming a commission on Autism,” but said “no decisions have been made at this time.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

WSS

What should King Charles tell the public about his cancer?

New documents shed light on MD Anderson Cancer Institute feud

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Alabama hospital puts IVF treatments on hold

Gilead might be held responsible for not developing a drug

knowledge

comprehensive

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Alabama frozen embryo ruling has major implications for IVF clinics

After affirmative action ruling, medical educators look to 'holistic review'

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

How one medical school became remarkably diverse

Antivenom research: Lessons from HIV applied in search for universal antidote

Trump demands the U.S. pay no more for drugs than other countries … again

Biogen Alzheimer’s drug launch off to slow start

Medical leaders decry Supreme Court decision on affirmative action

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

leisure time

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Obesity drugs seen as possible treatment for liver disease MASH

Gilead might be held responsible for not developing a drug

Gilead might be held responsible for not developing a drug

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

R1 RCM gets $5.8 billion buyout offer from private equity firm

focus

focus

knowledge

focus